Skip to main content
. 2021 Jan 18;8(1):111–118. doi: 10.1002/acn3.51251

Table 4.

Differential rate of cerebral atrophy (BPF) by disease phenotype in placebo group.

Estimated rate of BPF decline over 48 weeks

(95% CI)

P‐value
PPMS placebo patients −0.00254 (−0.00334, −0.00173)
SPMS placebo patients −0.00108 (−0.00195, −0.00022)
Difference (PPMS – SPMS) −0.00146 (−0.00264, −0.00027) <0.02